Biotech

All Articles

Gilead pays J&ampJ $320M to go out licensing deal for seladelpar

.Along With Gilead Sciences almost an FDA decision for its liver condition medication seladelpar, th...

' All palms on deck' at Lilly as peers target weight problems market

.Chief executive officer David Ricks can view the firms establishing tents at basecamp responsible f...

Entero laying off personnel, leaving office as well as stopping R&ampD

.Cushion Liquidators has turned Entero Rehabs white as a sheet. The creditor got Entero to repay its...

Exelixis drops ADC after determining it's no match for Tivdak

.Exelixis is actually quiting on its cells factor (TF)- targeting antibody-drug conjugate after wrap...

Relay loses interest in SHP2 prevention after Genentech leaves behind

.3 weeks after Roche's Genentech unit left an SHP2 prevention pact, Relay Therapy has actually valid...

Stoke's Dravet syndrome med launched of predisposed scientific grip

.Stoke Therapies' Dravet disorder medication has been actually without a partial hold, getting rid o...

Fierce Biotech's Gabrielle Masson offers Strong 15 at NYSE

.Brutal Biotech Associate Editor Gabrielle Masson provided the 2024 course of Tough 15 winners on th...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH possibility

.Novo Nordisk has axed its once-monthly dual GLP-1/ GIP receptor agonist, ending (PDF) development o...

Daiichi pays out Merck $170M to develop lung cancer T-cell engager deal

.Merck &amp Co. has quickly recovered several of the prices of its own Weapon Rehabs buyout, attract...

BioMarin halts preclinical genetics therapy for heart condition

.After BioMarin administered a spring season clean of its own pipeline in April, the business has ac...